Antiarrhythmic drug

ApprovedSmall molecule

YYonsei University

Antiarrhythmic drug is one of 120 small molecule programs targeting Atrial Flutter. It is currently in Approved.

Indications

Total Trials

Active Trials

119

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atrial FlutterActive, not recruiting

Cognitive ImpairmentActive, not recruiting

Ventricular TachycardiaActive, not recruiting

Paroxysmal Atrial FibrillationActive, not recruiting

Atrial FibrillationActive, not recruiting

Atrial FlutterPreclinical

Active, not recruiting

Cognitive ImpairmentPreclinical

Active, not recruiting

Ventricular TachycardiaPreclinical

Active, not recruiting

Paroxysmal Atrial FibrillationPreclinical

Active, not recruiting

Atrial FibrillationApproved

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Antiarrhythmic drug

YYonsei University

Approved

4 2

Calquence

AstraZeneca

Preclinical

1 3

Calan

VVal Adams

Preclinical

4 4

Rituxan

Roche

Preclinical

—5

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 6

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 8

Brukinsa

BBeOne Medicines

Preclinical

1 9

Imbruvica

PPharmacyclics LLC.

Preclinical

1 10

Xylocaine

MMEDRx USA, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

N/ARecruiting

Cognitive Impairment

NCT05790707

Q3 2030

Recruiting

Ventricular Tachycardia

NCT06455488

Clinical

Trials by Indication[1]

Ventricular Tachycardia4 trials

MANAGE-VT Registry - MANAGEment of Ventricular Tachycardia Outcomes Registry

Recruiting·CCorVita Science Foundation··NCT06455488·130 enrolled

Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation

Terminated·VVanderbilt University Medical Center·Phase 3·NCT04208997·5 enrolled

Trial to Evaluate the Efficacy and Safety of Substrate Ablation of Monomorphic Ventricular Tachycardia

Completed·HHospital General Universitario Gregorio Marañon·N/A·NCT03734562·180 enrolled

Show 1 more trial

Prospective Randomized Clinical Trial for Effect of Stellate Ganglion Block in Medically Refractory Ventricular Tachycardia

Unknown status·YYonsei University·N/A·NCT02646501·20 enrolled

Atrial Fibrillation4 trials

CRyoAblation vs AntiaRrhythmic Drugs for Persistent Atrial Fibrillation Trial

Completed·HHospital San Carlos, Madrid·Phase 4·NCT03716934·196 enrolled

The Safety and Efficacy of Pulsed Field Ablation for Patients With Persistent Atrial Fibrillation Comorbid With HFpEF.

Enrolling by invitation·—·N/A·NCT07077811·158 enrolled

Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation

Completed·HHospital Clinic of Barcelona·Phase 4·NCT00863213·152 enrolled

Show 1 more trial

Kansai Plus Atrial Fibrillation Trial

Completed·KKyoto University, Graduate School of Medicine·Phase 4·NCT01477983·2,113 enrolled

Paroxysmal atrial fibrillation3 trials

STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation

Completed·MMedtronic Cardiac Ablation Solutions·N/A·NCT03118518·225 enrolled

Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation

Withdrawn·—·Phase 4·NCT01505296

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation

Completed·BBiosense Webster, Inc.·Phase 3·NCT00116428·167 enrolled

Atrial Flutter1 trial

Therapy of Atrial Flutter by Afib Ablation

Unknown status·UUniversity of Rostock·N/A·NCT02051621·100 enrolled

Pediatrics1 trial

Use of Antiarrhythmic Drugs in Pediatrics

Unknown status·—··NCT04863001·100 enrolled

1 more indication

Cognitive impairment1 trial

EfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment

Recruiting·PPoitiers University Hospital·N/A·NCT05790707·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Antiarrhythmic drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antiarrhythmic drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antiarrhythmic drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: YYonsei University

Antiarrhythmic drug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2030

Trials by Indication[1]

Ventricular Tachycardia4 trials

Atrial Fibrillation4 trials

Paroxysmal atrial fibrillation3 trials

Atrial Flutter1 trial

Pediatrics1 trial

Cognitive impairment1 trial

References

Drug Info

Quick Facts

Related News